What is the study about?

To assess the clinical effectiveness of tranexamic acid (TXA) after Intracerebral Haemorrhage (ICH) and determine whether TXA should be used in clinical practice. 

Primary objective: To assess the effect of TXA on early death (≤7days) 

Secondary objective: To assess the effect of TXA on dependency 6 months after ICH. 

Who can take part in the study?

Adults within 4.5 h of onset of acute spontaneous ICH (confirmed on brain imaging). When onset of symptoms is unknown patient must be within 4.5 hours of symptom discovery and have no other exclusion criteria.

What are we trying to find out?

The objective is to assess the clinical effectiveness of tranexamic acid (TXA) after stroke versus usual care. With the primary objective being assess the effect of TXA on early deaths and the secondary objective to assess the effect of TXA on dependency 6 months after Intracerebral Haemorrhage (ICH). The team are measuring the cost effectiveness of TXA versus usual care. Incremental cost effectiveness ratios (ICERs), net monetary benefit and cost effectiveness of usual care versus TXA. HE data collection will include Health Care Resource Use and the EQ5D-5L

Funder

National Institute for Health and Care Research - Health Technology Assessment (NIHR - HTA)

Useful links